Working at iTeos

Job descriptions

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.

iTeos Therapeutics has the ambition to become a world-class actor in the sector and is continually looking for ways to bring life entrepreneurs to build iTeos, creative scientists who can expand iTeos’ expertise and deliver new drugs to patients. iTeos is growing significantly at this time and if you are excited about our vision and values, send your resume to jobs@iteostherapeutics.com and tell us how you can contribute to the success of iTeos Therapeutics.